Orphazyme A/S IPO Research Information

Orphazyme A/S IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Orphazyme A/S, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Orphazyme A/S	ORPH - NASDAQ	$13.13-$13.13	$11.00	$10.80	7.6 million ADSs	9/29/2020
Underwriter(s): BofA Securities, Cowen, Guggenheim
Co-Manager(s): Danske Markets
Industry: Health Care
Filing(s): Filed 2020-09-04 Terms Added 2020-09-21 Free Writing Prospectus 2020-09-25

Orphazyme A/S Quote & Chart - Click for current quote - ORPH

About Orphazyme A/S (adapted from Orphazyme A/S prospectus):
They are a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "ORPH" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.